Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Kedudukan dalam Saham #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Harga Saham
$0.16328419
Modal Pasaran
$204.14K
Perubahan (1 hari)
4.35%
Perubahan (1 tahun)
102.45%
Negara
GB
Perdagangan Fusion Antibodies plc (FAB)

Kategori

Healthcare
Pendapatan untuk Fusion Antibodies plc (FAB)
Pendapatan pada Sep 2025 TTM: $-2.06M
Menurut laporan kewangan terkini Fusion Antibodies plc, pendapatan semasa syarikat ialah $-2.06M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $-2.89M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $-3.53M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Fusion Antibodies plc dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -992,770.77%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -225,408.48%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -253,916.57%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -103,830.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -70,512.80%
NL